Compare Digital Realty Trust, Inc. (DLR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Mesoblast Limited — how do they compare? Digital Realty Trust, Inc. trades at $178.21 (market cap $65.32B), while Mesoblast Limited trades at $14.18 (market cap $1.75B). The key difference: Digital Realty Trust, Inc. is far larger — about 37.3× Mesoblast Limited's market cap, and Digital Realty Trust, Inc. pays a 2.77% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Mesoblast Limited for 14 Days on average.
| DLR | MESO | |
|---|---|---|
Market Cap | $65.32B | $1.75B |
Volume | 2,563,950 | 239,027 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $20.96 |
52-Week Low | $147.93 | $13.19 |
Typical Hold Time | 94 Days | 14 Days |
Enterprise Value | $84.03B | $1.83B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Digital Realty Trust (DLR) trades at $180.47, down 2.26% today, with a bearish technical signal despite strong analyst support. The data center REIT shows robust revenue growth to $6.11B in 2025 and expanding AI infrastructure partnerships, though valuation metrics remain elevated with a P/E of 85.89. Recent earnings show mixed results with Q2 2026 beating expectations by 150%.
DLR presents a compelling AI infrastructure play with strong growth prospects but faces valuation concerns and execution risks. The consensus price target of $222.35 suggests 23% upside potential, supported by 69% analyst buy ratings. Key risks include high leverage and competitive pressures in the rapidly expanding data center market.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
